Poonam A. Arora
Long/short equity, value, research analyst, biotech

Puma Biotechnology: ISPY2 Data Added Little To The Neratinib Conversation

At the American Association for Cancer Research (AACR) 2014 meeting, Puma Biotechnology (NYSE:PBYI) presented additional data on their Phase II ISPY2 study that evaluated Neratinib + Paclitaxel against Herceptin + Paclitaxel as treatment for breast cancer in the neo-adjuvant setting. On December 4, PBYI reported the graduation of the Neratinib + Paclitaxel regimen from the ISPY2 study. At AACR, the company provided more detail on the prior news including that only the HER2+ hormone receptor [HR] negative group had graduated. In addition, PBYI provided color on pathological complete response (pCR) rates, safety data, and biomarker outcomes.

pCR Results from the HER2+ HR Negative and HER2+ HR Negative/HR Positive Subgroups

In the HER2+ HR negative group, PBYI reported...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details